Background: In the Netherlands, 45% of all cancer cases occur in men and women aged 70 years and older. Since the population is ageing and cancer incidence rises with age, the number of new malignancies in the elderly is increasing. It has become apparent that there is a relationship between age at diagnosis and the treatment received. Therefore, age-spe cific variations in patterns of care for six common forms of cancer in the elderly, are examined.
younger counterparts, the diagnosis of elderly breast, colo rectal and lung cancer patients was more often based solely on clinical grounds. In the total study population, 16% were not treated, Per age category 50-59 years, 60-69 years and 704-these percentages were 7%, 12% and 22%, respectively, (P-trend = 0.001). For all malignancies the chance of not re ceiving treatment increased with increasing age. However, the size and nature of the differences varied with the localisation of the tumour. The proportion of untreated patients was par ticularly high in the patients with lung cancer and metastatic colorectal and ovarian cancer, and there was an increase with increasing age (P-trend = 0.001). The vast majority of pa Introduction selected on the grounds of not having any coniorhid conditions. Steady increases in the survival length of cancer pa-Existing literature gives the impression, that a greater tients and of life expectancy as such in the Netherlands proportion of elderly patients are not treated or receive are expected to lead to an increase in the prevalence of less intensive treatment (e.g., in terms of monotherapy cancer. A t present, over 45% of incident cancer paversus combination therapy) than younger patients [4tients in the Netherlands are older than 70 years at 11], In addition, there is hesitance about administering diagnosis [1] . Very little knowledge is available on the chemotherapy to elderly patients and, not infrequently, course of disease in the elderly, or more importantly, on a potentially curative operation is not performed bespecific treatment policies for elderly cancer patients, cause the risk is assumed to be too high [12] [13] [14] [15] . It is Knowledge about treatment methods is mainly based not the elderly patients themselves who choose less on experience with patients younger than 70 years, intensive treatment, although for them toxicity and Clinical trials often apply the same age limit [2, 3] . In quality of life do weigh more heavily [16] . A survey by the few studies that included elderly patients, they were telephone revealed that treating physicians were less in-6 7 8 clined to offer alternative treatment modalities to elderly patients [17] . We performed a study on the differences in diagnos tics and treatment between young and elderly cancer patients in the M iddle and Southern part of the prov ince of Limburg. The study group comprised patients with several com m on forms of cancer: breast, colorec tal, lung, ovarian, head and neck cancer and non-Hodgkin lymphoma. Besides the high incidence of these comm on tumours, variation in treatment modal ities was a basis for selection.
Patients and methods

Data collection
Data on incident cancer cases and data on diagnostic procedures and treatment were obtained from the Regional Cancer Registry Limburg, a department of the Comprehensive Cancer Centre Lim burg (IKL). This population-based Cancer Registry covers the regions of M iddle and South Lim burg with about 850,000 inhabi tants and 8 hospitals (for a description of the region and registration procedures see [18] ).
Study population
Patients aged 50 years and older who were diagnosed between 1 January 1988 and 31 December 1992 with breast cancer (n -1637), colorectal cancer (n = 1935), lung cancer (n « 2341), ovarian cancer (n = 255), head and neck cancer (n -412) or a non-Hodgkin lymphoma (n = 331) were included in the study (total n -6911). We excluded patients who had had an earlier malignancy and those in whom the diagnosis had not been made until autopsy.
Definitions and o p erationnlis Alton
Age
The patients were divided into three age categories: 50-59 years, 60-69 years and 70 years and olden
Tumour stage
In the IKL-registry tumour stage is registered according to the TNM classification system, the A nn A rbor staging system for lymphomas and the FI G O classification system for gynaecological tumours [19] . Tumour stage referred to the extent o f the disease at the time of making the definitive decision about the treatment policy. For the current study, the simplified staging system was used: stage 1, 2 , 3, or 4 and stage unknown. For the analysis of treatment by age, various stages were grouped together on the basis of similarities in general treatment modalities (see Table 1 ).
Grade of m alignancy
Owing to the fact that in non-Hodgkin lymphoma more than in any other malignancy, classification according to malignancy grade plays a major role in determining the choice of treatment and the prog nosis [20] , this factor was also included in the analysis. clinical (anamnesis and physical examination), cytological or histo logical; the latter was considered to be the most valid. The certainty factor is a measure of the extent and reliability of the examination procedures used for staging [19] . If there were insufficient data on the tumour (T), regional lymph nodes (N) or distant metastases (M) in the medical file, that part of the T N M was coded CO. The cer tainty factor was recorded as C l when data were available from standard examination procedures (anamnesis, X-ray photographs), C2 when data were available from more advanced examination procedures and C3 if surgical exploration had taken place. Per type of cancer (except for non-Hodgkin lymphomas because no C factor was recorded for them) we determined the proportion of patients per age category in whom the stage could be determined but for whom one or more parts of the T N M had a certainty factor of 0 (CO).
Treatment
Treatment concerned the primary treatment received by the patient in the first three months after diagnosis, in terms of: surgery, radio therapy, chemotherapy, endocrine treatment, other therapy, all pos sible combinations of these, and no treatment. Treatment policies for patients with lung cancer were analysed separately for small-cell lung cancer and non-small-cell lung cancer patients. Because the distinction between small-cell and non-small-cell lung cancer is based on the microscopically-confirmed morphology of the tumour, the basis for diagnosis was not analysed separately in order to avoid the risk of selection bias.
A n overview of regular treatment policies for the various malig nancies in the IKL-region was made by two clinical consultants from the Comprehensive Cancer Centre Limburg (HS, JJ), an internistoncologist and a radiotherapist-oncologist (see Table 1 ). 
Data analysis
For each malignancy we analysed the relationship between age and the extent of the diagnostic work-up, and between age and treatment by using the Pearson Chi-square test and the Mantel-Haenszel chisquare test for trend. As the treatment for cancer depends on the extent of the tumour, for each malignancy we also analysed the rela tionship between tumour stage and the age category of the patient. W ith the aid of models based on logistic regression (SAS, procedure LOG1ST) we evaluated the extent to which the age at diagnosis of each malignancy influenced the chance of not receiving treatment. These analyses were corrected for the effects of stage and sex.
Results
year olds versus 26% and 24% in the two other age categories. This was also true for colorectal cancer, 25%, 19% and 17%, respectively. When the proportion of unknown stages was added, this difference tended to disappear for the colorectal group but only partially disappeared for the head and neck cancer group.
Sometimes the stage of the disease was based on less extensive staging examinations (certainty factor = 0 for T, N or M). This phenomenon was associated with in creasing age, although this was not statistically signifi cant (see Tables 2 and 3 )*
Malignancy grade General
In the elderly patients with non-Hodgkin lymphomas, malignancy grade was unknown in a larger proportion The total study population comprised 6911 patients than in the younger patients: 26% in the 70+ age cat-(3515 men and 3396 women). The percentages of men egory versus 15% and 22% in the younger age categoin the lung cancer group, the head and neck tumour ries (P = 0*014). Moreover, more of the elderly patients group, the non-Hodgkin lymphoma group and the had a high or intermediate malignancy grade than the colorectal tumour group were 91%, 79%, 48% and younger patients (Table 4) . 49%, respectively.
Treatment Diagnosis
In the total study population, 16% were not treated
The diagnosis was confirmed histologically in 88% of (n ™ 1081). Per age category 50-59 years, 60-69 years the total patient population. Per age category 50-59 and 70+ these percentages were 7%, 12% and 22%, years, 60-69 years and 70+ these percentages were respectively (P-trend = 0.001). 93%, 90% and 83%, respectively. In the patients with
In 12% of the complete study population, the stage breast, lung and colorectal cancer there was a signifi-of the tumour was unknown; 51% of these patients cant increase in the proportion of patients without his-were not treated. Per age category 50-59 years, 60-69 tological or cytological confirmation with increasing years and 70+, these percentages were 23%, 45% and age, but proportions were very small. For ovarian can-58%, respectively (P-trend = 0.001), A higher age was cer, 14% of the diagnosis of elderly patients was based significantly associated with an unknown stage and no on cytological grounds, while this was only 2% in the treatment. Although this applied to all malignancies, younger age categories. Also for lung cancer, cytologi-the percentages differed to some extent per site and cal confirmation of the diagnosis played a fairly major varied from 9%, 9% and 16% per age category in the role. In 20% of these patients the diagnosis was con-breast cancer group to 38%, 58% and 74% in the pafirmed cytologically (see Table 3 ). In the three age cat-tients with non-small-cell lung cancer (see Tables 2, 3 egories 50-59 years, 60-69 years and 70+ years, the and 4). diagnosis was confirmed cytologically in 16%, 17% and
In the patients with stage 1, 2 or 3 at diagnosis (n -24%, respectively (P-trend = 0.001).
4519, excluding the non-Hodgkin lymphomas), overall 5% were not treated. Per age category 50-59 years, 60-69 years and 70+, this was 2%, 4% and 8%, respective ly (P-trend " 0.001), For stage 1-3 patients there was Classification of tumour stage per age category is wide variation in the proportions of untreated patients shown in Tables 2, 3 and 4. For all malignancies, the per malignancy (see Tables 2 and 3) , The proportion stage was unknown in a larger proportion of the elderly was particularly high in the patients with lung cancer patients than the younger patients. The difference was and there was an increase with increasing age (Pstatistically significant in all the malignancy groups, trend ■ » 0.001). Treatment patterns showed that a single except for non-Hodgkin lymphoma and ovarian cancer treatment modality was applied more often to the (the two smallest groups). In the colorectal and lung elderly patients than to the younger ones; for colorectal tumour groups, this was associated with a lower pro-cancer this was surgery, for ovarian cancer this was surportion of elderly patients with more advanced stage gery or only chemotherapy, for non-small-cell lung candisease, whereas in the breast and ovarian cancer cer this was radiotherapy and for breast cancer this was groups, the proportion of women with stage 4 disease surgery or endocrine therapy. In contrast, more of the increased with increasing age. Furthermore, a relatively younger patients received combination therapy, which large number of young patients with advanced stage head and neck cancer was found: 41% in the 50-59 depended on the localisation. Particularly in the breast cancer group, there were many more different treat- a Thoroughness of staging diagnostics, derived from the certainty factor. These percentages are only valid for the patients with a known stage* b S +RT for head and neck cancer; S + ET for breast cancer; S + CT for ovary' and colorectal cancer. a Thoroughness of staging diagnostics, derived from the certainty factor. These percentages are only valid for the patients with a known stage. l) The stage of small-cell lung carcinoma is coded according to 'extend o f disease'. Limited disease stage 1, extensive disease -* stage 4. c Occult stage: the primary tum our could not be evaluated, or the presence of a tum our was detected through malignant cells in sputum or bronchial rinsing, but was not visible on a chest X-ray or at bronchoscopy (T X , NO, MO). For analysis these patients were classified under stage 1. ll Radiotherapy for non-small-cell lung cancer; chemotherapy for small-cell lung cancer. ment combinations in the younger patients than in the in combination with surgery. The younger patients were 70+age category given more often a combination of surgery and chemo-In the total group of patients with metastatic cancer therapy than the elderly (see Table 2 ). The vast major-(n = 1126 excluding the non-Hodgkin lymphomas), ity (94%) of patients with metastatic breast cancer re-36% were not treated. Per age category 50-59 years, ceived treatment, which usually comprised endocrine 60-69 years and 70+, this was 20%, 30% and 40%, therapy (44%) or a combination of surgery and endorespectively (P-trend = 0.001). A bout 38% of the pa-crine therapy (20%); however, more of the elderly tients with a metastatic non-small cell lung tumour women only received endocrine therapy than the were treated, mainly with radiotherapy (23%). This dif-younger ones. Nearly all of the patients with metastatic fered substantially from the percentage with a small cell head and neck cancer were treated (91%). They re tumour: 80% received treatment, mainly chemotherapy ceived surgery and radiotherapy (43%) or only radio-(73%). For the patients with stage 4 ovarian cancer it therapy (30%); this also applied to the elderly patients, was found that a remarkable high proportion of pa-Furthermore, it was found that in the patients with a tients received chemotherapy (64%), from which 28% metastatic colorectal tumour, more of the women aged 70+ years did not receive treatment than the men with in this age category, 40% and 21%, respectively. Other wise no sex differences were found. The elderly patients with a non-Hodgkin lymphoma stage I received radiotherapy (35%), surgery (22%) or chemotherapy ( 12%), while the younger patients re ceived more often a combination of these treatments (see Table 4 ).
681
The majority of patients with a non-Hodgkin lym phoma stage 2, 3 or 4 received chemotherapy, but the percentage decreased with increasing age. In the three age categories 50-59 years, 60-69 years and 70+, the percentages were 77%, 75% and 57%, respectively (jP** 0.023). When the malignancy grade was also in cluded in the analysis (data not shown), we found that only 10% of the patients with low grade disease, stage 1 (n =* 11), received radiotherapy alone, whereas this per centage was 45% in the patients with intermediate or high grade disease. In the patients with low grade dis ease, stage 2, 3 or 4, 50% received chemotherapy and 18% were not treated, whereas 74% of the patients with intermediate or high grade disease, stage 2, 3 or 4 re ceived chemotherapy and 7% were not treated. The majority of patients who were not treated were 70 years of age or older.
The logistic regression analyses showed that, cor rected for stage and sex, the chance of not receiving treatment increased with increasing age (see Table 5 ). In the colorectal cancer group, the effect of higher age depended on the tumour stage and the sex of the pa tient (see Table 6 ). The effect of age on the chance of not being treated was greater for women of 70 years and older than for men. Owing to the fact that nearly all of the breast cancer patients were treated, we investi gated the effect of age on the chance of receiving one " Adjusted for stage and sex. 95% confidence interval. 0 Reference category, (i The effect of age 70+ was different for men and women and depended on stage. Therefore, the odds ratios are presented sepa rately. treatment modality versus a combination of two or Lung cancer on the contrary, revealed large age-spe- Table 7 . Odds ratios and 95% confidence intervals for one treat ment modality versus two or more treatment modalities according to age; breast cancer, age 50 years and older. IK L 1988 IK L -1992 more modalities. The results showed that a higher age cific differences in the diagnostic work-up and treatat diagnosis increased the chance of only receiving one ment methods. This was probably related with the fact type of treatment (see Table 7 ). that lung cancer still has a very poor prognosis. For example with non-metastatic non-small-cell lung can cer, older age decreased the likelihood of receiving sur gery: 61% of the patients in the age category 50-59 years were operated on, while this was 50% in the 60-69 year olds and only 30% in those of 70+ years. A reluctancy to operate on elderly patients was described earlier by Smith et al, [21] for locoregional NSCLC. They studied differences in treatment patterns of lung cancer with data from incident cases from the Virginia Cancer Registry, 1985 Registry, -1989 In their study comorbid ity did not appear to have influence. However, over the past few years, various authors have argued in favour of considering tumour resection in elderly patients with a non-small cell lung carcinoma [15, 22] , For breast and ovarian cancer, the total of stage 4 and stage unknown is much higher in elderly patients, which may indicate patient delay, A high percentage of Age-specific differences in the diagnostics and treat-elderly patients with advanced stage disease is in ment of patients with various forms of cancer, diag-agreement with some studies [6, 23, 24] but not with nosed in the period 1988-1992, were investigated* other [25, 26] . Especially for breast cancer the litera-Data on incident cancer cases and data on diagnostic ture on the age-stage relationship is inconsistent [27] . 
Discussion
procedures and treatment were obtained from the Since the end of the 1980s, it was recommended not population-based Regional Cancer Registry Limburg, to treat elderly breast cancer patients with endocrine Several findings indicated that elderly patients had therapy alone (usually Tamoxifen) [6, [28] [29] [30] . This undergone a less extensive diagnostic work-up: a larger policy was also recommended in our region and we proportion of unknown tumour stage among the elder-found that a considerable proportion of the elderly ly, a higher proportion of patients without a histologi-patients received a combination of surgery and endocally or cytologically confirmed diagnosis, and a higher crine therapy: 27% for stage 1-3 patients and 12% for proportion of patients in whom the stage was based on stage 4 patients. However, 14% of the elderly patients less accurate diagnostic procedures (certainty factor), with breast cancer stage 1-3 and 59% of the elderly Furthermore, it could be concluded that a higher age patients with advanced stage disease received endoincreased the chance of not being treated or of receiv-crine therapy alone. ing less intensive treatment.
In the elderly patients with a metastatic colorectal The extent of the diagnostic work-up was derived tumour (// « 178), more elderly women than elderly from the basis for diagnosis and from the degree of cer-men did not receive treatment, 40% and 21%, rcspectainty about the TN M classification (certainty factor), tively, which is in agreement of earlier findings |8|. Our classification according to the certainty factor was However, within this wide age category the average age rather rigorous and may have caused some misclassifi-of the women was higher than that of the men. Pro lo cation. For example, a lung tumour which had a CO for ably there was also more comorbid disease among the M, but C2 for T and C2 for N, which can be enough elderly women. information to make the decision not to operate, was
One of the factors that is of great importance for the valued in this study as being insufficient diagnostic prognosis of a patient with a non-Hodgkin lymphoma work-up. Also a rather high proportion of the certainty is the malignancy grade. In this study we found that 22% of the N H L patients could not be classified, Partly this was due to the fact that the diagnosis was based factor was missing for one or more parts of the TNM . Nevertheless, an association was found between the diagnostic work-up according to the certainty factor upon cytology only. Also, there is no classification and age, suggesting a less extensive work-up at higher according to the Working Formulation for a group of age. The degree to which diagnostics and treatments dif fered and the nature of these differences depended on the localisation of the tumour. For head and neck can-lymphomas which comprise 5% of the total of lympho mas (e.g., T-cell lymphoma). However, these two phe nomena do not completely explain the high proportion of unclassified lymphomas, which may be partially due cer, for example, there were hardly any age-specific dif-to a registration artefact. Furthermore, we had to be ferences in the treatment modalities applied. It is pos-cautious with our analyses on this patient group, sible that the heterogeneity within this group of because stratifying the patients according to stage, tumours obscured any differences. malignancy grade and age sometimes produced very 2, 3.
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Also we did not have any information about comor bidity in our population of cancer patients, or about their functional and cognitive status, social circum stances and education level. These factors may have helped to explain why a patient had a less intensive 4, diagnostic work-up or a less intensive treatment. A d vanced stage disease with the associated series of diag nostic tests may be considered to be too much of a burden by a patient with poor physical or mental health, or by the family or the treating physician. In addition, if the treating physician feels defeatism or has misgivings about the efficacy of the treatment, this may lead to a less intensive policy. In the literature available on this subject, there is no consensus about the role that these factors play in the choice of treatment. In some studies, the age effect on the choice of treatment remained intact after correction for comorbidity [4, 8] , while in others the effect disappeared [14] , Within the group of elderly patients in the USA, associations have been found between no treatment and civil status, socio-economic status, transport facilities and the dis-11. tance between home and the treatment centre [8, 30] . 5.
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In this study we confirmed the existence of age-specific differences in the diagnostics and treatment of cancer patients. However, we are just as much in the dark about the decision-making process about diagnos-13. tics and therapy in the elderly, as we are about the con sequences of the age-specific differences observed, e.g., consequences for the patient in terms of survival and quality of life. In a group of breast cancer patients, Bergman et al. [6] found a difference in treatment be tween the younger and elderly patients, but not in sur-15* vival. Gloeckler Ries [7| on the contrary concluded that for ovarian cancer, there were differences between treatment and survival: the younger patients had rela tively higher survival chances than the older patients.
If the decision not to treat a patient is based on dis-17. ease progression and on misgivings about treatment efficacy [14] , then why is it that so many younger patients with more advanced stage cancer do receive treatment, while the older ones do not? Maybe we are 19. under-treating the older patients, or over-treating the younger ones? More research is necessary to provide answers to these questions.
